T. Rixecker

Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.

M. Ziepert, M. Pfreundschuh, S. Dietrich, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Suboptimal dosing of rituximab in male and female patients with DLBCL.

N. Schmitz, M. Pfreundschuh, M. Wiesen, 2014, Blood.

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.

M. Pfreundschuh, M. Hallek, L. Trümper, 2014 .

Parenthood in long‐term survivors after CHOP with or without etoposide treatment for aggressive lymphoma

M. Ziepert, M. Pfreundschuh, A. Ho, 2014, British journal of haematology.

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Michael Hallek, Ulrich Keller, Mathias Witzens-Harig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Carsten Müller, M. Pfreundschuh, M. Wiesen, 2012, Blood.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

C. Rübe, M. Ziepert, N. Schmitz, 2017, British journal of haematology.

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.

M. Pfreundschuh, M. Hallek, L. Trümper, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.

M. Ziepert, M. Pfreundschuh, G. Hasenfuss, 2015, Pharmacogenomics.